Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-16
2007-10-16
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S069100, C435S455000
Reexamination Certificate
active
09863803
ABSTRACT:
Disclosed are methods for treating a vascular graft that include introducing an effective amount of at least one nucleic acid encoding at least one agent that increases activated protein C (APC), expressing the agent in the cells; and increasing the APC sufficient to treat the blood vessel. Also provided are vascular grafts engineered to resist early and/or late graft failure.
REFERENCES:
patent: 5571786 (1996-11-01), Eibl et al.
patent: 5804392 (1998-09-01), Esmon et al.
patent: 5852171 (1998-12-01), Fukudome et al.
patent: 6290949 (2001-09-01), French et al.
patent: 6309380 (2001-10-01), Larson et al.
patent: 6399064 (2002-06-01), Fukudome et al.
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/13807 (1993-07-01), None
patent: WO 96/05303 (1996-02-01), None
patent: WO 96/06933 (1996-03-01), None
patent: WO 97/30083 (1997-08-01), None
Kim et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance implications for vein graft failure pp. 205-212 2002.
Valley et al. Supplement II Circulation vol. 104, No. 17 2001.
Miller et al. Targeted vectors for gene therapy pp. 190-199 vol. 9 1995.
Deonarain Ligand-targeted receptor-mediated vectors for gene delivery pp. 53-69 1998.
Newby et al. Targets for gene therapy of vein grafts pp. 489-494 1999.
Bowie et al, Science Mar. 1990; 247:1306-10.
Rudinger, Peptide Hormones 1976; Jun. pp. 1-7.
Thomas et al, Transplant 1999;68:1660-73.
Stephens et al, J Autoimmun 1997;10:293-8.
Skolnick et al. TIBTECH Jan. 2000;18:34-9.
Vassalli et al, Cardiovasc Res 1997,35:459-69.
Game et al, Wien Klin Wochenschr 2001;113:823-38.
Platt et al, Nat Biotech Mar. 2002;20(3)231-2.
Hardy et al, J Virol 1997;71:1842-9.
Qing et al, J Virol 1997;71:5663-7.
Newby et al, Curr Opin Cardiol 1999;14:489-94.
Soares et al, J Immunol 1998;161:4572-82.
Kim et al, Circ Res 2002;90:205-12.
Dittman, et al. 1990. “Structure and Function of Thrombomodulin” Blood 75, No. 2: pp. 329-336.
C. Esmon. 1989. “The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation” J. of Biol. Chem. vol. 264, No. 9: 4743-4746.
Lundell, et al. 1999. “Reduction in Vascular Lesion Formation by Hirudin Secreted From Retrovirus-Transduced Confluent Endothelial Cells on Vascular Grafts in Baboons” Circulation 100: 2018-2024.
Motwani, et al. 1998. “Aortocoronary Saphenous Vein Graft Disease” Circulation 97:916-931.
Rade, et al. 1996. “Local Adenoviral-Mediated Expression of Recombinant Hirudin Reduces Neointima Formation After Atreial Injury” Nature Medicine vol. 2, No. 3: 293-298.
Waugh, et al. 2000. “Thrombomodulin Overexpression to Limit Neointima Formation” Circulation 102: 332-337.
Waugh, et al. 1998. “Local Overexpression of Thrombomodulin for In Vivo Prevention of Arterial Thrombosis in a Rabbit Model” Circ Res 84: 84-92.
Rade, et al. 1998. “Retroviral Vector-Mediated Expression of Hirudin By Human Vascular Endothelial Cells: Implications for the Design of Retroviral Vectors Expressing Biologically Active Proteins” Gene Therapy 6: 385-392.
PCT International Search Report, 4 pages.
Lin, et al., “Modulation of Glycosaminoglycan Addition in Naturally Expressed and Recombinant Human Thrombomodulin”; The Journal of Biological Chemistry, vol. 269, No. 40, pp. 25021-25030, 1994.
Tsiang, et al., “Functional Domains of Membrane-bound Human Thrombomodulin”; The Journal of Biological Chemistry, vol. 267, No. 9, pp. 6164-6170, 1992.
Kurosawa, et al., “Proteolytic Formation and Properties of Functional Domains of Thrombomodulin”; The Journal of Biological Chemistry, vol. 262, No. 5, pp. 2206-2212, 1987.
Ye, et al., “The Fifth and Sixth Growth Factor-like Domains of Thrombomodulin Bind to the Anion-binding Exosite of Thrombin and Alter Its Specificity”; The Journal of Biological Chemistry, vol. 267, No. 16, pp. 11023-11028, 1992.
Kurosawa, et al., “A 10-kDa Cyanogen Bromide Fragment from the Epidermal Growth Factor Homology Domain of Rabbit Thrombomodulin Contains the Primary Thrombin Binding Site”; The Journal of Biological Chemistry, vol. 263, No. 13, pp. 5993-5996, 1988.
Clarke, et al., “The Short Loop between Epidermal Growth Factor-like Domains 4 and 5 Is Critical for Human Thrombomodulin Function”; The Journal of Biological Chemistry, vol. 268, No. 9, pp. 6309-6315, 1993.
Stearns, et al., “Microthrombomodulin”; The Journal of Biological Chemistry, vol. 264, No. 6, pp. 3352-3356, 1989.
Parkinson, et al., “Stable Expression of a Secretable Deletion Mutant of Recombinant Human Thrombomodulin in Mammalian Cells”; The Journal of Biological Chemistry, vol. 265, No. 21, pp. 12602-12610, 1990.
Regan, et al., “The Interaction between the Endothelial Cell Protein C Receptor and Protein C Is Dictated by the γ-Carboxyglutamic Acid Domain of Protein C”; The Journal of Biological Chemistry, vol. 272, No. 42, pp. 26279-26284, 1997.
Xu, et al., “Metalloproteolytic Release of Endothelial Cell Protein C Receptor”; The Journal of Biological Chemistry, vol. 275, No. 8, pp. 6038-6044, 2000.
Fukudome, et al., “Molecular Cloning and Expression of Murine and Bovine Endothelial Cell Protein C/Activated Protein C Receptor (EPCR)”; The Journal of Biological Chemistry, vol. 270, No. 10, pp. 5571-5577, 1995.
Fukudome, et al., “The Endothelial Cell Protein C Receptor”; The Journal of Biological Chemistry, vol. 271, No. 29, pp. 17491-17498, 1996.
J. M. Breuss, et al., “Adenoviral Gene Transfer of IkappaB Into Ballooned Rabbit Iliac Arteries For Prevention of Neointima Formation”, Abstract, FASEB Journal, vol. 13, No. 4, 1999, 1 page.
Dennis E. Hallahan, “Nuclear Factor kB Dominant Negative Genetic constructs Inhibit X-ray Induction of Cell Adhesion Molecules in the Vascular Endothelium”, Cancer Research, vol. 58, No. 23, 1998, 5 pages.
J. A. Brockman, et al., “Coupling of a Signal Response Domain in I-kappa-B-alpha to Multiple Pathways for NF-kappa-B Activation”, Abstract, Molecular and Cellular Biol., vol. 15, No. 5, 1995, 1 page.
Ingrid H. C. Vos, et al., “NFkB decoy oligodexynucleotides reduce monocyte infiltration in renal allografts”, FASEB Journal, vol. 14, No. 5, 2000, pp. 814-822.
Tam T. T. Huynh, et al., “Control of Intimal Hyperplasia By Local Modulation of NF-kB Activity In Experimental Vein Grafts”, Abstract, Surgical Forum, vol. 48, 1997, 4 pages.
Giuseppe Vassalli, et al., “Gene therapy for arterial thrombosis”, Cardiovascular Research, vol. 35, No. 3, 1997, Abstract, 11 pages.
Johannes Breuss, et al., “Adenoviral gene transfer of I-kappa-B into ballooned rabbit iliac arteries for prevention of restenosis” Abstract, Vascular Biology, vol. 96, No. 11, 2000, 1 page.
PCT International Search Report, 4 pages, May 1, 2002.
Kim Antony Y.
Rade Jeffrey J.
Sohn Richard H.
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Li Q. Janice
Sparks Jonathan M.
The Johns Hopkins Univeristy
LandOfFree
Genetic engineering of vascular grafts to resist disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic engineering of vascular grafts to resist disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic engineering of vascular grafts to resist disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834547